7 Result(s)
-
Article
Open AccessComparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investi...
-
Article
Open AccessMelanoma and immunotherapy bridge 2015
MELANOMA BRIDGE 2015
-
Article
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Exploration for biomarkers for drugs that block immune checkpoints should be rationally conducted based on knowledge of the mechanism of action of the targeted...
-
Article
Open AccessSafety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
Limited adjuvant treatment options exist for patients with high-risk surgically resected melanoma. This first-in-human study investigated the safety, tolerability and immunologic correlates of Melanoma GVAX, a...
-
Article
Open AccessWorkshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunother...
-
Article
Structural basis for the recognition of mutant self by a tumor-specific, MHC class II–restricted T cell receptor
Structural studies of complexes of T cell receptor (TCR) and peptide–major histocompatibility complex (MHC) have focused on TCRs specific for foreign antigens or native self. An unexplored category of TCRs inc...
-
Article
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were ...
